# Ocular Therapeutix (OCUL) — News

OCUL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ocul/news

## Recent headlines

- [Wuhan Hiteck Biological Pharma Co - Grants Visara exclusive rights to HT006.2.2 outside Greater China](https://www.ainvest.com/news/wuhan-hiteck-biological-pharma-grants-visara-exclusive-rights-ht006-2-2-greater-china-2610) — AInvest Wire, Oct 13, 2026
  Wuhan Hiteck Biological Pharma Co has entered into an exclusive licensing agreement with Visara, granting the latter rights to HT006.2.2 outside the Greater China region. The terms of the agreement were not disclosed in detail, but such partnerships are common in the biopharmaceutical industry to…
- [Ocular Therapeutix targets 2027 launch for AXPaxli in wet AMD](https://www.ainvest.com/news/ocular-therapeutix-targets-2027-launch-axpaxli-wet-amd-2609) — AInvest Wire, Sep 15, 2026
- [Ocular Therapeutix announces positive pre-NDA meeting with U.S.](https://www.ainvest.com/news/ocular-therapeutix-announces-positive-pre-nda-meeting-2609) — AInvest Wire, Sep 15, 2026
  Ocular Therapeutix, Inc. (NASDAQ: OCUL) has announced a positive outcome from its pre-NDA meeting with the U.S. Food and Drug Administration (FDA), further aligning its regulatory pathway for the New Drug Application (NDA) submission of AXPAXLI for the treatment of wet age-related macular…
- [Rival Ocular Therapeutix shares up 8%](https://www.ainvest.com/news/rival-ocular-therapeutix-shares-8-2608) — AInvest Wire, Aug 17, 2026
  Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares rose approximately 8% in afternoon trading on August 17, 2026, following the company’s announcement of a regulatory milestone. The biopharmaceutical firm disclosed that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the…
- [Ocular Therapeutix shares up 12.7% premarket after rival Eyepoint's eye drug misses main goal in late-stage trial](https://www.ainvest.com/news/ocular-therapeutix-shares-12-7-premarket-rival-eyepoint-eye-drug-misses-main-goal-late-stage-trial-2608) — AInvest Wire, Aug 17, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).